Paediatric ALL perspective

Bookmark and Share
Published: 12 Nov 2021
Views: 132
Rating:
Save
Prof Andrea Biondi - University of Milano-Bicocca, Milan, Italy

Prof Andrea Biondi talks to ecancer following his talk at ALL Assembly 2021.

He begins by explaining that Ph+ ALL (Philadelphia chromosome-positive ALL) is a relatively rare sub-group of ALL among paediatric patients up to the age of 18. Up until the event of the first TKI (Tyrosine Kinase Inhibitors) the prognosis of this disease was very dismal. The only way to treat a child with Ph+ ALL was to get the disease into remission and then perform a stem cell transplantation as soon as possible. The overall survival rate was less than 40%.

Prof Biondi then goes on to say that the landscape was changed with the event of the TKI, where overall survival boosted from 40% to 70%. By reducing the need for bone marrow transplantation the long term side effects were also reduced. However, it was observed that there was a significant increase in toxicity from intensive chemotherapy + TKI.

He then concludes by saying that he strongly believes that an alternative approach, including immunotherapy, might provide a different landscape in either reduction of toxicity, or by further improving treatment effectiveness for this sub-group of ALL.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related Videos

WCLC 2021: Epidemiology of MET Exon 14 mutations
Dr Anna Minchom, Dr Alex Spira, Prof Byoung Chul Cho and Prof Albrecht Stenzinge...
WCLC 2021: Epidemiology of MET Exon 14 mutations ( Dr Anna Minchom, Dr Alex Spira, Prof Byoung Chul Cho and Prof Albrecht Stenzinger )
19 Oct 2021
Acetylsalicylic acid added to atezolizumab bevacizumab combo does not improve ef...
Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK
Acetylsalicylic acid added to atezolizumab bevacizumab combo does not improve efficacy in ovarian, fallopian, peritoneal cancer ( Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK )
24 Sep 2021
Drug combination shows promise in treatment-resistant advanced ovarian cancer
Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK
Drug combination shows promise in treatment-resistant advanced ovarian cancer ( Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK )
24 Sep 2021
Erdafitinib (ERDA) or ERDA plus cetrelimab for patients with metastatic or local...
Prof Thomas Powles - Queen Mary University of London, London, UK
Erdafitinib (ERDA) or ERDA plus cetrelimab for patients with metastatic or locally advanced urothelial carcinoma (mUC) and FGFRa ( Prof Thomas Powles - Queen Mary University of London, London, UK )
17 Sep 2021
Safety and efficacy of isatuximab plus bortezomib, lenalidomide, and dexamethaso...
Dr Enrique Ocio - Marqués de Valdecilla University Hospital, Santander, Spain
Safety and efficacy of isatuximab plus bortezomib, lenalidomide, and dexamethasone combined therapy for NDMM ( Dr Enrique Ocio - Marqués de Valdecilla University Hospital, Santander, Spain )
14 Sep 2021
Iberdomide in combination with dexamethasone and daratumumab, bortezomib, or car...
Prof Sagar Lonial - Winship Cancer Institute of Emory University, Atlanta, USA
Iberdomide in combination with dexamethasone and daratumumab, bortezomib, or carfilzomib in RRMM patients ( Prof Sagar Lonial - Winship Cancer Institute of Emory University, Atlanta, USA )
14 Sep 2021
Mitomycin and BCG treatment vs BCG monotherapy in patients with non-muscle invas...
Dr Cosimo De Nunzio - Sant'Andrea Hospital, University La Sapienza, Rome, Italy
Mitomycin and BCG treatment vs BCG monotherapy in patients with non-muscle invasive bladder cancer ( Dr Cosimo De Nunzio - Sant'Andrea Hospital, University La Sapienza, Rome, Italy )
19 Jul 2021
Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or ...
Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA
Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer ( Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA )
14 Jun 2021
Real world evidence on the use of antibody drug conjugates in peripheral T-cell ...
Prof Ali Bazarbachi - American University of Beirut-Medical Center, Beirut, Leba...
Real world evidence on the use of antibody drug conjugates in peripheral T-cell lymphoma ( Prof Ali Bazarbachi - American University of Beirut-Medical Center, Beirut, Lebanon )
14 Jun 2021